@article{3102621,
    title = "Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens",
    author = "Do, O.A. and Ferris, L.A. and Holt, S.K. and Ramos, J.D. and Harshman, L.C. and Plimack, E.R. and Crabb, S.J. and Pal, S.K. and De Giorgi, U. and Ladoire, S. and Baniel, J. and Necchi, A. and Vaishampayan, U.N. and Bamias, A. and Bellmunt, J. and Srinivas, S. and Dorff, T.B. and Galsky, M.D. and Yu, E.Y.",
    journal = "Clinical Genitourinary Cancer",
    year = "2021",
    volume = "19",
    number = "2",
    pages = "125-134",
    publisher = "HANLEY & BELFUS-ELSEVIER INC",
    issn = "1558-7673",
    doi = "10.1016/j.clgc.2020.10.006",
    keywords = "carboplatin;  cisplatin;  fluorouracil;  gemcitabine;  pemetrexed;  taxane derivative;  antineoplastic agent;  cisplatin, adult;  aged;  Article;  cancer chemotherapy;  cancer control;  cancer recurrence;  cancer surgery;  cancer survival;  chemoradiotherapy;  comparative effectiveness;  comparative study;  controlled study;  female;  human;  major clinical study;  male;  metastasis;  multicenter study (topic);  multiple cycle treatment;  overall survival;  progression free survival;  retrospective study;  transitional cell carcinoma;  bladder tumor;  transitional cell carcinoma;  treatment outcome, Antineoplastic Combined Chemotherapy Protocols;  Carcinoma, Transitional Cell;  Cisplatin;  Humans;  Retrospective Studies;  Treatment Outcome;  Urinary Bladder Neoplasms",
    abstract = "Background: Optimal chemotherapy for patients who received cisplatin for localized urothelial carcinoma (UC) and develop metastatic disease is unclear. We compared the efficacy of platinum-based (PBC) versus non–platinum-based (NPBC) first-line chemotherapy for metastasis. Patients and Methods: Data were collected from the Retrospective International Study of Cancers of the Urothelial Tract (RISC), a database of 3024 patients from 28 international academic centers from 2005 to 2012. Patient inclusion criteria included: (1) predominant UC; (2) any primary tumor site; (3) cT2-4, cN0-N2, cM0; (4) prior receipt of perioperative/radiation cisplatin-containing chemotherapy; and (5) receipt of cytotoxic chemotherapy in the first-line metastatic setting. Multivariate Cox proportional hazards models were used to show progression-free survival (PFS) and overall survival (OS) from the first day of chemotherapy for metastatic disease to date of censor. Results: Eligibility criteria was met by 132 patients (n = 74 PBC; n = 58 NPBC). The median OS was 8.13 months (interquartile range, 4.87-16.64 months) and 8.77 months (interquartile range, 4.01-13.49 months) for PBC and NPBC, respectively. Neither OS (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.64-1.69; P =.87) nor PFS (HR, 0.86; 95% CI, 0.56-1.31; P =.48) differed for PBC versus NPBC. However, for patients who received chemotherapy more than a year after perioperative/radiation chemotherapy, OS was superior for PBC over NPBC (HR, 0.31; 95% CI, 0.10-0.92; P =.03). Conclusions: There is no significant outcome difference between PBC and NPBC in patients with metastatic UC who previously received cisplatin-based chemotherapy for localized disease. However, if over a year has elapsed, return to PBC is associated with superior OS. © 2020 Elsevier Inc."
}